10 reports

In April 2002, Faes Farma filed a patent application (US##/ ##, ##) entitled Polymorph of ##-[##-[##-[##-(##-ethoxyethyl)-##Hbenzimidazole-##-yl]-##-piperidinyl] ethyl]-αα-dimethyl-benzeneacetic acid".

  • Allergy Drug
  • Therapy
  • Canada
  • United States
  • Product Initiative

In April 2002, Faes Farma filed a patent application (US##/ ##, ##) entitled Polymorph of ##-[##-[##-[##-(##-ethoxyethyl)-##Hbenzimidazole-##-yl]-##-piperidinyl] ethyl]-αα-dimethyl-benzeneacetic acid".

  • Allergy Drug
  • Therapy
  • Canada
  • United States
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Allergy Drug
  • OTC
  • Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • Japan
  • World

The prominent features of this report are - ##.

  • Allergy
  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • World

The prominent features of this report are - ##.

  • Allergy Drug
  • Clinical Trial
  • World
  • Product Initiative
  • UCB S.A.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Allergy Drug
  • Drug Development
  • Pharmaceutical
  • Respiratory Disease
  • World

The prominent features of this report are - ##.

  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • Japan
  • World

RESEARCHERS IDENTIFIED TWO MARKERS, CYTOKINE IL-## ALPHA AND IL-##.

  • Allergy Drug
  • Dermatological Condition
  • Therapy
  • Company
  • Product Initiative
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Allergy Drug
  • Clinical Trial
  • Pharmaceutical
  • World
  • Product Initiative